What Genetic Testing Can (and Cannot) Tell Us About Cannabis Response
People can experience the same cannabis product very differently. Dose, THC and CBD content, tolerance, age, health status, other medications and environment all matter—and genetic variation may be one factor among many.
A 2013 study provides an example of the question researchers are investigating. In a sample of 144 people, including 86 cannabis users and 58 nonusers, researchers examined two genetic variants: COMT Val158Met and the serotonin-transporter variant 5-HTTLPR. The study found that cannabis users carrying a COMT Val allele made more monitoring and shifting errors than users with the Met/Met genotype. The researchers also reported genotype-related differences in sustained attention and decision-making.
These findings do not show that a person’s genotype determines how they will respond to cannabis. The study was observational, measured performance on specific cognitive tasks and could not establish that the genetic variants caused the differences. Nor did it demonstrate that one genotype is suited to a particular cannabis strain. The original research is available in the 2013 study published in Neuropsychopharmacology.
Other human research has reported that COMT variation may influence sensitivity to THC-related cognitive effects, but the results remain limited and context-dependent. A double-blind, placebo-controlled study involving 74 participants found that Val-allele carriers were more sensitive to some THC-related memory and attention impairments than Met-allele carriers. The researchers also cautioned that responses could depend on pre-existing vulnerability to psychosis and other gene-environment interactions.
Those findings have helped fuel interest in cannabis pharmacogenomics—the study of how genetic variation may affect the metabolism and effects of cannabinoids. Commercial services such as Navigator Genomics Testing have marketed cheek-swab tests intended to analyze genes involved in cannabinoid metabolism, drug response and potential medication interactions. Their reports have used simplified categories to indicate whether a substance may warrant routine use, caution or avoidance.
The concept is plausible in principle. THC and CBD are metabolized partly through liver enzymes including CYP2C9, CYP2C19 and CYP3A4, which also process many prescription medicines. A 2024 systematic review of cannabinoid drug interactions found evidence that cannabis or cannabinoids can alter medication levels in some circumstances, although much of the available research involves small studies, case reports or products with poorly characterized doses and compositions.
That distinction is important. A genetic result may eventually help clinicians adjust a standardized cannabinoid medicine or identify a possible metabolism issue, but it cannot account for every factor that shapes a person’s experience. Commercial cannabis products can differ substantially in potency, chemical profile, route of administration and labeling accuracy. The Centers for Disease Control and Prevention advises people to discuss cannabis use with a healthcare professional because cannabis may change how prescription drugs work.
Evidence for consumer cannabis genetic panels is also not the same as evidence for an FDA-authorized clinical test. The U.S. Food and Drug Administration’s guidance on direct-to-consumer genetic testing notes that tests can vary in the genes and variants they examine, and that results should not be the sole basis for medical decisions. The agency has specifically warned against relying on pharmacogenetic claims that have not been supported by appropriate clinical evidence.
Genetic testing may become useful as researchers conduct larger, better-controlled studies that connect specific variants with measured THC or CBD exposure, standardized products, medication levels and clinical outcomes. For now, however, these tests should be viewed as experimental decision-support tools—not reliable systems for choosing a cannabis “strain” or replacing individualized medical advice.
